story of the week
Margetuximab vs Trastuzumab in Patients With Previously Treated HER2+ Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
J. Clin. Oncol 2022 Nov 04;[EPub Ahead of Print], HS Rugo, SA Im, F Cardoso, J Cortes, G Curigliano, A Musolino, MD Pegram, T Bachelot, GS Wright, C Saura, S Escrivá-de-Romaní, M De Laurentiis, GN Schwartz, TJ Pluard, F Ricci, WR Gwin, C Levy, U Brown-Glaberman, JM Ferrero, M de Boer, SB Kim, K Petráková, DA Yardley, O Freedman, EH Jakobsen, EN Gal-Yam, R Yerushalmi, PA Fasching, PA Kaufman, EJ Ashley, R Perez-Olle, S Hong, MK Rosales, WJ GradisharFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.